Since last decade, immunotherapy targeting PD-1/PD-L1 and their combination strategies including IC and IBC have revolutionized lung adenocarcinoma treatment, especially in patient with high PD-L1 expression (Li et al. 2023; Shao et al. 2022; Wenfan et al. 2023). Here, CD274 is linked to lung adenocarcinoma.